Overview

Efficacy and Safety of Rivaroxaban in the Management of Acute Non-neoplastic PVT Compensated Cirrhosis

Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
-Rivaroxaban is factor Xa inhibitor
Phase:
Phase 3
Details
Lead Sponsor:
Sherief Abd-Elsalam
Treatments:
Rivaroxaban